Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4901292 | 0.89 | PTPN1 (0.33) | ELANENR1H2PTPN1PTGS2PTPN2 | |
| SCHEMBL4901255 | 0.88 | PTPN1 (0.41) | ELANENR1H2PTPN1PTGS2PTPN2 | |
| SCHEMBL4903141 | 0.85 | NR1H2 (0.34) | ELANENR1H2PTPN1PTGS2TBXA2R | |
| SCHEMBL4900105 | 0.83 | NR1H2 (0.32) | ELANENR1H2PTPN1PTGS2 | |
| SCHEMBL4901627 | 0.82 | KMT2A (0.34) | PTGS2 | |
| SCHEMBL4901617 | 0.81 | MKNK1 (0.33) | ELANEPTGS2 | |
| SCHEMBL5802847 | 0.80 | ELANE (0.36) | ELANENR1H2PTGS2TBXA2RPTGDR | |
| SCHEMBL4894177 | 0.80 | PTPN1 (0.35) | ELANENR1H2PTPN1PTGS2PTPN2 | |
| SCHEMBL4891877 | 0.77 | PTGS2 (0.33) | ELANEPTPN1PTGS2PTPN2PRMT5 | |
| SCHEMBL4901235 | 0.76 | PTGS1 (0.33) | ELANEPTPN1PTGS2PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070867-A1 | 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases | METABASIS THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| WO-2006078698-A1 | 2-IMIDAZOLONE AND 2-IMIDAZOLIDINONE HETEROCYCLIC INHIBITORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070867-A1 | 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases | PPM1B, PPM1D, PTPRS | ELANE 4393/4885NR1H2 2792/4885PTPN1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.